Lan-lan Pang

State Key Laboratory Of Oncology In South China
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ.

EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ.

Journal: The Journal of clinical investigation

Published: April 15, 2025

Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation.

Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation.

Journal: Neoplasia (New York, N.Y.)

Published: September 11, 2024

Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis.

Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 25, 2024

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 29, 2023

Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.

Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 21, 2023

Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma.

Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma.

Journal: International journal of cancer

Published: August 06, 2022

Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis.

Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis.

Journal: BMJ open

Published: June 13, 2022

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.

Journal: BMC cancer

Published: April 05, 2022

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.

Journal: Cancer

Published: March 09, 2022

Longitudinal Bowel Behavior Assessed by Bowel Ultrasound to Predict Early Response to Anti-TNF Therapy in Patients With Crohn's Disease: A Pilot Study.

Longitudinal Bowel Behavior Assessed by Bowel Ultrasound to Predict Early Response to Anti-TNF Therapy in Patients With Crohn's Disease: A Pilot Study.

Journal: Inflammatory bowel diseases

Published: September 05, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026